Vanderbilt Team Using Mass Spec to Research Cancer Immunotherapy – GenomeWeb
|
Vanderbilt Team Using Mass Spec to Research Cancer Immunotherapy
GenomeWeb Currently, PD-L1 is the most commonly measured marker in cancer immunotherapy with patient levels typically assessed using immunohistochemistry. However, Liebler said, there are a number of questions around the performance and standardization of … |
